Our Services
Medical Information
Helpful Resources
Published on: 9/17/2026
Most common diltiazem side effects, including dizziness, headache, flushing, fatigue, and mild ankle swelling, tend to begin within the first few days and often ease within one to two weeks as your body adjusts. Constipation and leg swelling can persist longer and sometimes require a dose adjustment, and extended-release formulations may take longer to settle because the medication is released gradually throughout the day. How long symptoms last also depends on your dose, kidney and liver function, age, and other medications you take, so there are several important factors to consider below. Warning signs such as a very slow heart rate, fainting, worsening shortness of breath, or rapidly increasing swelling are not typical adjustment effects and warrant prompt medical evaluation. Because it can be hard to tell a temporary adjustment from a reaction that needs attention, taking a free, instant, online symptom check can help you clarify what your symptoms may mean and decide whether to call your prescriber, seek urgent care, or simply keep monitoring.
Last reviewed for medical accuracy: 09/17/2026
Diltiazem is a calcium channel blocker commonly prescribed for high blood pressure, chest pain (angina), and certain heart rhythm disorders. Like all medications, it can cause side effects—most of which are mild and tend to improve over time. Understanding when and why these side effects occur, and how long they may last, can help you feel more in control as you begin treatment.
While every individual is different, here’s what you can generally expect after starting diltiazem:
These tend to be rare, but if they occur, they can be more serious. They may appear early or develop over weeks:
If you notice any of these, seek medical help immediately or contact emergency services.
Dosage and Formulation
Individual Metabolism
Concurrent Medical Conditions
Duration of Therapy
Most side effects improve within days to a couple of weeks. If you experience:
consider a free, online symptom check, using the doctor approved Ubie Symptom Checker, to better understand your situation and decide if urgent care or a doctor’s visit is needed.
Side effects from diltiazem are often mild and tend to resolve as your body adjusts—typically within the first one to two weeks. Some, like edema or slow heart rate, may last longer and require ongoing management. By monitoring your symptoms, staying in close contact with your healthcare provider, and making simple lifestyle adjustments, you can navigate these effects safely.
Remember, if you ever experience serious or life-threatening symptoms—or if you’re unsure how to interpret what you’re feeling—reach out immediately. Always speak to a doctor about anything that could be life threatening or serious.
(References)
* Conti CR, Pepine CJ, Feldman RL, Hill JA. Calcium antagonists. Cardiology. 1985;72(5-6):297-321. doi: 10.1159/000173886. PMID: 2866840.
* Scheinman MM, Hess DS. New antiarrhythmic drugs. Am J Surg. 1983 Jun;145(6):724-32. doi: 10.1016/0002-9610(83)90129-0. PMID: 6407348.
* Leonard RG, Talbert RL. Calcium-channel blocking agents. Clin Pharm. 1982 Jan-Feb;1(1):17-33. PMID: 6764159.
* Nykamp D, Winter EE. Olmesartan medoxomil-induced angioedema. Ann Pharmacother. 2007 Mar;41(3):518-20. doi: 10.1345/aph.1H566. Epub 2007 Mar 6. PMID: 17341528.
* Hamadi A, Grigg AP, Dobie G, Burbury KL, Schwarer AP, Kwa FA, Jackson DE. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response. Thromb Haemost. 2019 Jul;119(7):1112-1123. doi: 10.1055/s-0039-1688787. Epub 2019 May 12. PMID: 31079415.
* Gallo P, De Vincentis A, Pedone C, Nobili A, Tettamanti M, Gentilucci UV, Picardi A, Mannucci PM, Incalzi RA, REPOSI Investigators. Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med. 2019 Jul;65:51-57. doi: 10.1016/j.ejim.2019.05.002. Epub 2019 May 10. PMID: 31084979.
* Siegel JD, Ko CJ. Diltiazem-associated Photodistributed Hyperpigmentation. Yale J Biol Med. 2020 Mar;93(1):45-47. Epub 2020 Mar 27. PMID: 32226335; PMCID: PMC7087047.
* Desai A, Mohammed T, Patel KN, Almnajam M, Kim AS. 5-Fluorouracil Rechallenge After Cardiotoxicity. Am J Case Rep. 2020 Aug 29;21:e924446. doi: 10.12659/AJCR.924446. Epub 2020 Aug 29. PMID: 32860674; PMCID: PMC7483515.
* Boldig K, Ganguly A, Kadakia M, Rohatgi A. Managing life-threatening 5-fluorouracil cardiotoxicity. BMJ Case Rep. 2022 Oct 17;15(10). doi: 10.1136/bcr-2022-251016. Epub 2022 Oct 17. PMID: 36253013; PMCID: PMC9577891.
* Heurtebize MA, Faillie JL. Drug-induced hyperglycemia and diabetes. Therapie. 2024 Mar-Apr;79(2):221-238. doi: 10.1016/j.therap.2023.09.010. Epub 2023 Oct 31. PMID: 37985310.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.